You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
摩通:上調君實生物(1877.HK)目標價至115港元 評級“增持”
格隆匯 02-23 15:36
格隆匯2月23日丨摩根大通發研報指,MSCI中國健康護理指數年初至今表現跑贏恆指4%,而部分生物科技企業表現超過該行近期上調的目標價。該行更新行業部分企業的模型及目標價,以反映持續的大量流動性、投資者對優質的新興生物科技公司及關鍵資產的全球機遇有強勁興趣。其中,給予君實生物(1877.HK)“增持”評級,將目標價由68港元上調至115港元,較2月22日收盤價80.1港元有超43%的潛在升幅。摩通表示,君實生物專注於發現、開發和商業化新型候選藥物,用於治療癌症、自身免疫性疾病和其他大量未被滿足的醫療需求。近日,公司鼻咽癌研究取得重大進展,特瑞普利單抗(商品名:拓益®)是中國首個批准上市的以PD-1為靶點的國產單抗藥物。此外,公司合作伙伴美國禮來製藥的在研抗體藥物Etesevimab及Bamlanivimab雙抗體療法目前已在美國和意大利獲得授權。該行認為,憑藉完整的生物製劑開發平台和廣闊的產品線,公司將從中國快速增長的生物製劑市場中受益。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account